Cyprus/Greece/MaltaCyprusGreeceMalta

US-Greek R&D-agreement signed

12.05.2006

Athens/Napa - Senetek PLC, a US-biopharmaceutical company focused on developing and co-marketing products in the key categories skincare and dermatological worldwide, announced in March that they have signed a cooperative research agreement with two noted researchers in Greece. They are: Dr. Efstathios S. Gonos, Director of Research of the Department of Molecular and Cellular Ageing, Institute of Biological Research and Biotechnology, of the National Hellenic Research Foundation, and his colleague Dr. Ioanna Chinou, Associate Professor of the Division of Pharmacognosy-Chemistry of Natural Products, School of Pharmacy, Athens University. Gonos and Chinou are examining a class of plant extracts and various analogs for their proteasome activation and damaged protein scavenging bioactivity. The agreement gives Senetek exclusive access to all of the Researchers' scientific data within this category and provides for Senetek to participate in funding the testing and development of all selected compounds. The contract also covers the filing and prosecution of new patents covering related inventions, with Senetek having the option to enter into exclusive global licenses under the Researchers' existing patent applications and to jointly develop patents for all future applications.

Cyprus/Greece/MaltaCyprusGreeceMalta

10.12.2011

Athens – Greek researchers have called on members of the international research community to sensitise their governments to the problems in their country’s research landscape. “The orderly execution of the badly needed reforms...

Cyprus/Greece/MaltaCyprusGreeceMalta

01.10.2011

Athens – The supply of innovative bio­pharmaceuticals to Greek hospitals has broken down. Swiss Roche AG has pulled the plug by stopping delivery of drugs for cancer and other diseases to some state-funded hospitals. Among them...

Cyprus/Greece/MaltaCyprusGreeceMalta

10.06.2011

Athens – The situation in the pharmaceutical market in Greece increasingly looks to be spiralling out of control. According to the Financial Times, the Greek government already appears to be unable to pay healthcare companies...

Cyprus/Greece/MaltaCyprusGreeceMalta

10.07.2010

Athens – The Novo Nordisk Group has restarted sales of its insulin products in Greece. At the beginning of June, the Danish pharmaceutical company had pulled out 17 products – mostly insulin or insulin analogues – after the Greek...

Cyprus/Greece/MaltaCyprusGreeceMalta

11.03.2010

Athens – A EUR2.5m EU research project targeting olfaction in the malaria carrier Anopheles gambiae is to be coordinated by Greek researchers from the Institute of Bio­logy at the Demokritos National Centre of Scientific Research...

Cyprus/Greece/Malta, PolandCyprusGreeceMalta

29.04.2009

Nicosia – Golgi Pharmaceuticals Ltd is strengthening its collaboration with London-based ReGen Therapeutics. The Cypriot firm will produce and package Colostrinin tablets, and expand distribution to Greece and other Balkan...

Cyprus/Greece/MaltaCyprusGreeceMalta

29.04.2009

Athens –The 5th International Biotechnology Forum (IGBF5), which is to be held May 8-9 in Athens, boasts appearances by three Nobel Prize winners. Andrew Schally, Richard Roberts and Sir Peter Mansfield will speak at the opening...

Cyprus/Greece/MaltaCyprusGreeceMalta

16.04.2009

Golgi Pharmaceuticals of Cyprus is strengthening its collaboration with London-based ReGen Therapeutics. Golgi will produce tablets of and package Colostrinin, and expand distribution to Greece and other Balcan countries....

Cyprus/Greece/MaltaCyprusGreeceMalta

03.11.2008

Athens/Houston – Greece is planning to establish state-of-the-art clinics for stem cell therapy with associated stem cell banks. In mid-August, GloCal Investment Ventures Enterprise (G.I.V.E.) – a venture capital fund backed by...

Cyprus/Greece/MaltaCyprusGreeceMalta

18.08.2008

Athens – Greek diagnostics supplier Neo­medica has entered into a distribution agreement with Swedish Life Assays AB (Lund), a daughter of Chemel AB. Neo­medica, a specialist for point-of care tests, now has exclusive rights to...

Displaying results 1 to 10 out of 47

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-cyprus-greece-malta/article/us-greek-rd-agreement-signed.html

Stock list

All quotes

TOP

  • THROMBOGENICS (B)9.69 EUR9.24%
  • NOVACYT (F)4.80 EUR9.09%
  • HYBRIGENICS (F)1.85 EUR7.56%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • THERAMETRICS (CH)0.08 CHF-11.11%

TOP

  • WILEX (D)3.15 EUR303.8%
  • SANTHERA (CH)68.90 CHF102.6%
  • ADDEX (CH)4.06 CHF82.1%

FLOP

  • MERCK KGAA (D)64.28 EUR-49.5%
  • HYBRIGENICS (F)1.85 EUR-29.4%
  • PROSENSA (NL)9.24 USD-24.4%

TOP

  • SANTHERA (CH)68.90 CHF3433.3%
  • GW PHARMACEUTICALS (UK)422.75 GBP769.5%
  • PAION (D)2.80 EUR311.8%

FLOP

  • CYTOS (CH)0.26 CHF-92.4%
  • EVOCUTIS (UK)0.21 GBP-92.1%
  • THROMBOGENICS (B)9.69 EUR-69.2%

No liability assumed, Date: 23.07.2014


Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events